experimental compound AVI4658

A 26-week study by AVI BioPharma finds that intravenous AVI4658 appears safe and beneficial to Duchenne MD patients with mutations in or around exon 51

posted on October 15, 2010 - 1:12pm

The experimental drug AVI4658, in development by AVI BioPharma to treat Duchenne muscular dystrophy (DMD) caused by specific genetic mutations, was well tolerated and resulted in increased production of the needed dystrophin protein. Measured aspects of cardiac, pulmonary and skeletal muscle function remained stable.